FKB327

DRUG2 trials

Sponsors

Fujifilm Kyowa Kirin Biologics Co., Ltd.

Conditions

Arthritis, Rheumatoid

Phase 3

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

CompletedNCT02260791

Fujifilm Kyowa Kirin Biologics Co., Ltd.Arthritis, Rheumatoid

Start: 2014-12-31End: 2016-07-31Updated: 2017-11-28

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

CompletedNCT02405780

Fujifilm Kyowa Kirin Biologics Co., Ltd.Arthritis, Rheumatoid

Start: 2015-06-10End: 2018-01-18Updated: 2019-03-26

Related Papers

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.

2020-12-0134 citations

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.

2019-12-1238 citations

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the Rheumatic Diseases2018-03-07112 citations